1McKeage K,Goa KL.Insulin glargine:a review of its therapeutic use as a long-acting agent for the management of type 1 and 2 diabetes mellitus[J].Drugs,2001,61(11):1599-1624.
2Hamann A,Matthaei S,Rosak C,et al.A randomized clinical trical comparing breakfast dinner or bedtime administration of insulin glargine in patients with type 1[J].Diabetes Care,2003,26(6):1738-1744.
3Rosenstock J,Schwartz SL,Clark CM,et al.Basal insulin therapy in type 2 diabetes:28-week comparison of insulin glargine(HOE901)and NPH insulin[J].Diabetes Care,2001,24(4):631-636.
4Raptis SA,Hatziagelaki E,Dimitriadis G,et al.Comparative effects ofglimepiride and glibendamide on blood glucose,C-peptide and insulin concentrations of the fasting and postprandial state in normal men[J].Exp Clin Endocrinol diabet,1999,107(6):350-355.
5Rosenstock J,Dailey G.Massi-BenedettiM,et al.Reduced hypoglycemia risk with insulin glargine:a meta-analysis comparing insulin glargine with human NPH insulin in type 2 diabetes[J].Diabetes Care,2005,28:950-995.
6Janka HU,Raddh MC,Plewe G,et al.Comparison of basal insulin added to oral agents versus twice-daily permixed insulin as initial insulin therapy for type 2 diabetes[J].Diabetes Care,2005,28:254-259.
7Korytkowski M,Thomas A,Reid L,et al.Glimepiride improves both first and second phases of insulin secretion in type 2 diabetes[J].Diabetes Care,2002,25:1607-1611.
